RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial.
Normanno N, Esposito Abate R, Lambiase M, Forgione L, Cardone C, Iannaccone A, Sacco A, Rachiglio AM, Martinelli E, Rizzi D, Pisconti S, Biglietto M, Bordonaro R, Troiani T, Latiano TP, Giuliani F, Leo S, Rinaldi A, Maiello E, Ciardiello F; CAPRI-GOIM Investigators.
Normanno N, et al. Among authors: maiello e.
Ann Oncol. 2018 Jan 1;29(1):112-118. doi: 10.1093/annonc/mdx417.
Ann Oncol. 2018.
PMID: 28950295
Free article.
Clinical Trial.